Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Nov;26(6):466-472.
doi: 10.1097/MOH.0000000000000542.

Neonatal and pediatric platelet transfusions: current concepts and controversies

Ravi Mangal Patel  1 , Cassandra Josephson  1   2   3
Affiliations
Review

Neonatal and pediatric platelet transfusions: current concepts and controversies

Ravi Mangal Patel et al. Curr Opin Hematol. 2019 Nov.

Abstract

Purpose of review: In this review, we focus on three specific concepts related to platelet transfusion in the neonatal and pediatric population: choice of transfusion threshold; use of ABO-mismatched platelets; transfusion of pathogen-reduced or inactivated platelets.

Recent findings: Recent trials support the use of lower platelet transfusion thresholds (25 000/μl) in preterm neonates, although data is limited to guide transfusion among more mature neonates. In children, there is low-level evidence as to what the prophylactic platelet transfusion threshold should be in many situations of thrombocytopenia, revealing major variability in platelet transfusion practices. Most pediatric guidelines are extrapolated from adult studies with the most evidence in treatment-associated hypoproliferative thrombocytopenia varying between a platelet transfusion threshold of 10 000/μl to 20 000/μl. Although pathogen-reduced platelets may lower the risks of transfusion-transmitted infection, the effects on platelet refractoriness and transfusion burden in this population warrant additional study.

Summary: Our review highlights recent advances in neonatal and pediatric platelet transfusion and also emphasizes the urgent need for better evidence to guide practice given recent studies showing the potential harms of platelet transfusion, particularly with liberal use.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: CDJ is a consultant for Immucor, Inc and Octapharma, and is an investigator on a Mirasol study with Terumo.

References

    1. Venkatesh V, Curley A, Khan R, Clarke P, Watts T, Josephson C, et al. A novel approach to standardised recording of bleeding in a high risk neonatal population. Arch Dis Child Fetal Neonatal Ed. 2013;98(3):F260–3. - PubMed
    1. Sola-Visner M, Bercovitz RS. Neonatal Platelet Transfusions and Future Areas of Research. Transfus Med Rev. 2016;30(4):183–8. - PubMed
    1. Josephson CD, Su LL, Christensen RD, Hillyer CD, Castillejo MI, Emory MR, et al. Platelet transfusion practices among neonatologists in the United States and Canada: results of a survey. Pediatrics. 2009;123(1):278–85. - PubMed
    1. McPherson RJ, Juul S. Patterns of thrombocytosis and thrombocytopenia in hospitalized neonates. J Perinatol. 2005;25(3):166–72. - PubMed
    1. Keir AK, Yang J, Harrison A, Pelausa E, Shah PS, Canadian Neonatal N. Temporal changes in blood product usage in preterm neonates born at less than 30 weeks’ gestation in Canada. Transfusion. 2015;55(6):1340–6. - PubMed

Publication types

Substances